$INTI
Inhibitor Therapeutics, Inc.

2014 Q3 Form 10-Q Financial Statement

#000119312514308476 Filed on August 13, 2014

View on sec.gov

Income Statement

Concept 2014 Q3 2014 Q2 2013 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $570.0K $190.0K $290.0K
YoY Change 137.5% -34.48% 163.64%
% of Gross Profit
Research & Development $167.0K $1.930M $0.00
YoY Change -84.1%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $738.1K $2.116M $403.6K
YoY Change -42.89% 424.22% 266.89%
Operating Profit -$738.1K -$2.116M -$403.6K
YoY Change -42.89% 424.22%
Interest Expense $1.979K $24.99K $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $0.00 -$30.00K
YoY Change -100.0%
Pretax Income -$740.0K -$2.140M -$270.0K
YoY Change -42.64% 692.59% 125.0%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$740.1K -$2.141M -$266.9K
YoY Change -42.74% 702.03% 122.42%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.01 -$0.10 -$0.01
COMMON SHARES
Basic Shares Outstanding 41.42M shares 18.89M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q3 2014 Q2 2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $380.0K $270.0K $0.00
YoY Change -100.0%
Cash & Equivalents $375.9K $271.2K $1.112K
Short-Term Investments
Other Short-Term Assets $47.24K $29.29K $0.00
YoY Change -100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $423.1K $300.5K $0.00
YoY Change 377672.32% -100.0%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $423.1K $300.5K $0.00
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $423.1K $300.5K $0.00
YoY Change 377672.32% -100.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $331.0K $280.2K $140.0K
YoY Change 41.88% 100.12% -57.58%
Accrued Expenses $10.00K $20.00K $60.00K
YoY Change -66.67% -73.91%
Deferred Revenue
YoY Change
Short-Term Debt $40.00K $100.0K $0.00
YoY Change -42.86%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $432.6K $453.9K $310.0K
YoY Change -21.45% 46.41% -44.64%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $432.6K $453.9K $310.0K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $430.0K $450.0K $310.0K
YoY Change -21.93% 45.16% -82.78%
SHAREHOLDERS EQUITY
Retained Earnings -$31.32M -$30.58M
YoY Change 11.74%
Common Stock $21.14K $4.142K
YoY Change 1019.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$9.541K -$153.4K -$310.0K
YoY Change
Total Liabilities & Shareholders Equity $423.1K $300.5K $0.00
YoY Change 377672.32% -100.0%

Cashflow Statement

Concept 2014 Q3 2014 Q2 2013 Q2
OPERATING ACTIVITIES
Net Income -$740.1K -$2.141M -$266.9K
YoY Change -42.74% 702.03% 122.42%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$380.0K -$290.0K -$850.0K
YoY Change 216.67% -65.88% 750.0%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 490.0K 560.0K 70.00K
YoY Change 276.92% 700.0%
NET CHANGE
Cash From Operating Activities -380.0K -290.0K -850.0K
Cash From Investing Activities
Cash From Financing Activities 490.0K 560.0K 70.00K
Net Change In Cash 110.0K 270.0K -780.0K
YoY Change 1000.0% -134.62% 680.0%
FREE CASH FLOW
Cash From Operating Activities -$380.0K -$290.0K -$850.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
41419198 shares
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1112
CY2014Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41419198 shares
CY2014Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41419198 shares
CY2014Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9500000 shares
CY2014Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
340000000 shares
CY2014Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2014Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
31527255
CY2014Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
280172
CY2014Q2 us-gaap Notes Payable Current
NotesPayableCurrent
102420
CY2014Q2 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
-1100000
CY2014Q2 us-gaap Liabilities Current
LiabilitiesCurrent
453871
CY2014Q2 us-gaap Stockholders Equity
StockholdersEquity
-153354
CY2014Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
16296
CY2014Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-30584801
CY2014Q2 us-gaap Common Stock Value
CommonStockValue
4142
CY2014Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
300517
CY2014Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
52500
CY2014Q2 us-gaap Interest Payable Current
InterestPayableCurrent
2483
CY2014Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q2 us-gaap Assets Current
AssetsCurrent
300517
CY2014Q2 us-gaap Assets
Assets
300517
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
271226
CY2014Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
0
CY2014Q2 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
1100000
CY2014Q2 us-gaap Other Assets Current
OtherAssetsCurrent
29291
CY2014Q2 hppi Common Stock Shares Forfeitable
CommonStockSharesForfeitable
20000000 shares
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
857702
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18888971 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18888971 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9500000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
340000000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
27479913
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
287072
CY2013Q4 us-gaap Notes Payable Current
NotesPayableCurrent
68428
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
776053
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-765836
CY2013Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
366130
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-28247655
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
1889
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10217
CY2013Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
52500
CY2013Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1923
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Assets Current
AssetsCurrent
10217
CY2013Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
10000
CY2013Q4 us-gaap Assets
Assets
10217
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
217
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16976482 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-925854
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
us-gaap Revenues
Revenues
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-78371
us-gaap Operating Income Loss
OperatingIncomeLoss
-494124
us-gaap Net Income Loss
NetIncomeLoss
-327448
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
376800
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
69264
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-152836
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-856590
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
69264
us-gaap Operating Expenses
OperatingExpenses
494124
hppi Reorganization And Other Expenses
ReorganizationAndOtherExpenses
117324
hppi Net Cash Provided By Operating Activities Before Reorganization Items
NetCashProvidedByOperatingActivitiesBeforeReorganizationItems
-401913
hppi Increase Decrease In Liabilities Subject To Compromise
IncreaseDecreaseInLiabilitiesSubjectToCompromise
-357265
hppi Gain Loss On Reorganization
GainLossOnReorganization
166676
hppi Stock Payment In Lieu Of Cash
StockPaymentInLieuOfCash
152000
dei Entity Registrant Name
EntityRegistrantName
HedgePath Pharmaceuticals, Inc.
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2014-06-30
dei Entity Central Index Key
EntityCentralIndexKey
0001042418
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P3Y
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19760306 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-402629
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
1.00 pure
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
0 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <i>Estimates</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</p> </div>
us-gaap Revenues
Revenues
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
19291
us-gaap Operating Income Loss
OperatingIncomeLoss
-2302594
us-gaap Net Income Loss
NetIncomeLoss
-2337146
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
346787
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
673638
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
19282
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
271009
us-gaap Interest Expense
InterestExpense
34552
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
400000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1955807
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
273638
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
us-gaap Operating Expenses
OperatingExpenses
2302594
hppi Issuance Of Preferred Stock
IssuanceOfPreferredStock
1290726
hppi Debt Instrument Interest Rate Accrual Percentage
DebtInstrumentInterestRateAccrualPercentage
0.18 pure
hppi Issuance Of Warrants In Connection With Debt
IssuanceOfWarrantsInConnectionWithDebt
450000
hppi Net Cash Provided By Operating Activities Before Reorganization Items
NetCashProvidedByOperatingActivitiesBeforeReorganizationItems
-402629
hppi Noncash Interest Expense
NoncashInterestExpense
24666
hppi Common Stock And Warrants Issued
CommonStockAndWarrantsIssued
619134
hppi Stock Issued During Period Value Debt Forgiveness
StockIssuedDuringPeriodValueDebtForgiveness
189768
hppi Sharebased Compensation Arrangement Purchase Price Of Common Stock Percent Related To Specific Voting Stock Percentage
SharebasedCompensationArrangementPurchasePriceOfCommonStockPercentRelatedToSpecificVotingStockPercentage
1.10 pure
hppi Minimum Specified Voting Stock Percentage Under Incentive Stock Plan
MinimumSpecifiedVotingStockPercentageUnderIncentiveStockPlan
0.10 pure
hppi Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period Related To Specific Voting Stock Percentage
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodRelatedToSpecificVotingStockPercentage
P5Y
hppi Sale Of Common Stock Value
SaleOfCommonStockValue
250000
hppi In Process Research And Development Paid In Stock And Warrants
InProcessResearchAndDevelopmentPaidInStockAndWarrants
1909860
hppi Issuance Of Common Stock For Common Stock Subscription Receivable
IssuanceOfCommonStockForCommonStockSubscriptionReceivable
1100000
hppi Collection Of Stock Subscription Receivable
CollectionOfStockSubscriptionReceivable
150000
CY2013Q2 hppi Number Of Former Executive Officers To Whom Restricted Shares Issued
NumberOfFormerExecutiveOfficersToWhomRestrictedSharesIssued
1 Office
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18376899 shares
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2013Q2 us-gaap Revenues
Revenues
0
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-403580
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-266904
CY2013Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
30000
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
286256
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2115664
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-2140658
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
185182
CY2013Q2 us-gaap Operating Expenses
OperatingExpenses
403580
CY2013Q2 hppi Reorganization And Other Expenses
ReorganizationAndOtherExpenses
117324
CY2013Q2 hppi Gain Loss On Reorganization
GainLossOnReorganization
166676
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20622065 shares
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2014Q2 us-gaap Revenues
Revenues
0
CY2014Q2 us-gaap Interest Expense
InterestExpense
24994
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1930482
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
2115664

Files In Submission

Name View Source Status
0001193125-14-308476-index-headers.html Edgar Link pending
0001193125-14-308476-index.html Edgar Link pending
0001193125-14-308476.txt Edgar Link pending
0001193125-14-308476-xbrl.zip Edgar Link pending
d726474d10q.htm Edgar Link pending
d726474dex311.htm Edgar Link pending
d726474dex312.htm Edgar Link pending
d726474dex321.htm Edgar Link pending
d726474dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hppi-20140630.xml Edgar Link completed
hppi-20140630.xsd Edgar Link pending
hppi-20140630_cal.xml Edgar Link unprocessable
hppi-20140630_def.xml Edgar Link unprocessable
hppi-20140630_lab.xml Edgar Link unprocessable
hppi-20140630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending